Portola Marries Factor Xa Clot Buster Off To Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal is "strikingly similar" to a collaboration forged with Novartis for an anti-thrombotic earlier this year.
You may also be interested in...
Freed From Merck Deal, Portola Set To Move Betrixaban Forward With $89M Funding
Without a partner for its anticoagulant in an increasingly complex market, privately-held Portola takes $89 million in late-stage money to conduct Phase III trials on its own.
Back To The Drawing Board For Portola After Merck Returns Betrixaban
Merck & Co. returned the Phase III-ready oral Factor Xa inhibitor; Portola spins the news as an opportunity, but finding a new partner may be challenging.
Back To The Drawing Board For Portola After Merck Returns Betrixaban
Merck & Co. returned the Phase III-ready oral Factor Xa inhibitor; Portola spins the news as an opportunity, but finding a new partner may be challenging.